Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 1 | CN | 30 Jan 2022 | |
Breast Cancer | Phase 1 | CN | 30 Jan 2022 | |
Stomach Cancer | Phase 1 | CN | 30 Jan 2022 | |
Stomach Cancer | Phase 1 | CN | 30 Jan 2022 |